<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00785330</url>
  </required_header>
  <id_info>
    <org_study_id>DSHNHL 2004-R3</org_study_id>
    <nct_id>NCT00785330</nct_id>
  </id_info>
  <brief_title>Allo-hNHL (FluBuCy)</brief_title>
  <official_title>Open, Multicentral, Randomised Phase II Study of Allogene Stem Cell Transplantation After Pretreatment With Fludarabin, Busulfan, Cyclophospahmid and GVHD-Prophylaxis With or Without Rituximab in Patients With Recidivation of High Grade Non-Hodgkin's Lymphoma in Special Risk Situation in the Age of 18 - 65</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German High-Grade Non-Hodgkin's Lymphoma Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DSHNHL R3 is a randomized clinical phase II study. The main objective is to estimate the
      efficacy of rituximab as a prophylactic medication for prevention of
      graft-versus-host-disease after allogeneic peripheral stem cell transplantation in patients
      with a high risk relapse of aggressive B-cell Non-Hodgkin's lymphoma. The most important
      secondary objective is to estimate the efficacy of allogeneic stem cell transplantation in
      this clinical situation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in the age of 18 to 65 years with a high- risk relapse of a histology proven
      aggressive Non-Hodgkin's-lymphoma are eligible for the trial. Aggressive Non-Hodgkin's
      lymphoma within this study is defined as:

      B-NHL:

      follicular lymphoma grade III° lymphoblastic (precursor) lymphoma diffuse large cell cell
      lymphoma any subtype and variant including primary mediastinal lymphoma mantle cell lymphoma,
      blastic variant

      T-NHL:

      precursor T cell lymphoma peripheral T cell lymphoma, any subtype and variant
      angioimmunoblastic lymphoma anaplastic large cell lymphoma, any subtype NK / T cell lymphoma
      High risk relapsed or progressive disease is defined as (a) primary progressive disease, (b)
      early relapse after less than 12 month of remission duration and at least one risk factor
      according to the international prognostic index (IPI), (c) relapse or progression after high
      dose chemotherapy and autologous transplantation, (d) relapse or progression and lack of an
      autologous stem cell product.

      Patients with this type of progression / relapse should receive rituximab plus
      ifosfamide/carboplatin/etoposide (R-ICE) or rituximab plus dexamethasone/high dose
      ARA-C/cisplatinum as salvage therapy (recommendation, not part of study medication). In
      patients biwth T cell lymphoma rituximab may be replaced by alemtuzumab. If at least stable
      disease is achieved, patients can be definitely included.

      With inclusion, patients were randomized to receive either 375 mg/ m2 of rituximab at weeks
      3, 4, 5, 6, 25, 26, 27, 28 after allogeneic stem cell transplantation or no additional
      medication.

      Conditioning for transplantation consisted of Fludarabine 125 mg/m2, Busulfan 12 mg/kg and
      cyclophosphamide 120 mg/kg.

      Short-term (day 1 to day 28) mycophenolat mofetil and tacrolimus are used as basis GVHD
      prophylaxis in all patients. Anti-thymocyte globulin can be used due to the centres decision
      in patients with unrelated donors
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2004</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The specific measure that will be used to determine the effect of the intervention(s) or, for observational studies, related to core objectives of the study and receiving the most emphasis in assessment. (a) rate of acute GVHD grade II-IV after one year</measure>
    <time_frame>One year after allogeneic stem cell transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival, progression rate, non-relapse mortality, rate of grade 3-4 infectious adverse event, chronic GVHD</measure>
    <time_frame>one and three years after allogeneic SZT</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receiving no rituximab as GVHD prophylaxis after allogeneic SZT and only standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rituximab in addition to standard GVHD prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard GVHD prophylaxis</intervention_name>
    <description>Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Patients receiving 375 mg/ m2 of rituximab at weeks 3, 4, 5, 6, 25, 26, 27, 28 after allogeneic stem cell transplantation in addition to standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histology proven aggressive non Hodgkin's lymphoma and

          -  primary progressive disease or

          -  early relapse after less than 12 month of remission duration and at least one risk
             factor according to the international prognostic index (IPI or

          -  relapse or progression after high dose chemotherapy and autologous transplantation or

          -  relapse or progression and lack of an autologous stem cell product.

        Exclusion Criteria:

          -  severe comorbidity or impaired organ function

          -  hypersensitivity to used drugs

          -  HIV positivity

          -  active hepatitis

          -  other active malignant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertram Glass, Prof. MD.</last_name>
    <role>Study Director</role>
    <affiliation>Asklepios Klinik St. Georg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Würtenberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum und Poliklinik</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Goettingen</name>
      <address>
        <city>Göttingen</city>
        <zip>D.37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KMT-Zentrum Medizinische Klinik A</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.lymphome.de/Gruppen/DSHNHL/Protokolle/</url>
  </link>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>November 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2008</study_first_posted>
  <last_update_submitted>April 16, 2009</last_update_submitted>
  <last_update_submitted_qc>April 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. Glass</name_title>
    <organization>University Hospital Goettingen, Germany</organization>
  </responsible_party>
  <keyword>rituximab</keyword>
  <keyword>Non-Hodgkin's lymphoma</keyword>
  <keyword>diffuse large B cell lymphoma</keyword>
  <keyword>peripheral t cell lymphoma</keyword>
  <keyword>graft-versus-host disease</keyword>
  <keyword>graft-versus-lymphoma effect</keyword>
  <keyword>allogeneic haematopoietic stem cell transplantation</keyword>
  <keyword>relapsed or primary progressive aggressive Non-Hodgkin's lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

